表观基因组分析识别了使用HOPX的DTP亚群,以在肺腺癌中发展向治疗耐药性
Yang Tian1,2, Reshmee Bhattacharya1,2, Seungyeul Yoo3,4,5
1Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
iScience
|May 12, 2025
概括
肺癌中耐药的持久细胞表现出表观遗传调节. 针对发育途径和HOPX可以通过抑制肺癌再生来预防复发.
科学领域:
- 在瘤学瘤学.
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 分子生物学分子生物学
背景情况:
- 基因组研究确定了肺癌的致癌驱动因素,导致了向治疗.
- 尽管最初的反应,患者不可避免地经历由于耐药性持续性 (DTP) 细胞的瘤再生.
- 作为非遗传性耐药性的来源,DTPs的表观遗传调节仍然不太清楚.
研究的目的:
- 研究驱动药物耐受性持续性 (DTP) 细胞在肺癌中的生存的表观遗传机制.
- 识别不同的DTP子群及其监管途径.
- 探索针对DTP的潜在治疗策略,以防止癌症复发.
主要方法:
- 单细胞染色体可访问性分析 (scATAC-seq) 用于分析DTPs.
- 进行了综合网络和通路分析,以确定关键的分子通路.
- 进行基因删除和药物抑制研究以验证发现.
主要成果:
- 确定了两个不同的DTP亚群:一个与细胞循环相关,另一个与发育途径相关.
- 在发育次群中,膜特征基因HOPX被丰富,其删除延迟了DTP的再生.
- 霍普克斯调节NF-κB激活和基因素修饰,并结合抑制几乎取消了DTP的再生.
结论:
- 表观遗传调节,特别是涉及HOPX和发育途径,对于肺癌中DTP存活至关重要.
- 除了标准疗法之外,针对HOPX,NF-κB或胰岛素甲基转移酶提供了预防复发的潜在策略.
- 调节肺再生途径为患有肺癌的患者提供了一种新的抗复发方法.
相关概念视频
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
84
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
84
Pharmacogenomics: Identification of New Drug Targets
129
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
129


